2020
DOI: 10.3346/jkms.2020.35.e326
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Practice Guidelines for Prenatal Aneuploidy Screening and Diagnostic Testing from Korean Society of Maternal-Fetal Medicine: Cell-Free DNA Screening

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 40 publications
0
1
0
Order By: Relevance
“…Noninvasive prenatal testing (NIPT) is a method to screen for chromosomal abnormalities in the fetus, such as Down syndrome, Patau syndrome, and Edward syndrome, using cell-free DNA fragments from the fetus that are circulating in a pregnant woman's blood [1]. In particular, NIPT has been reported to have high sensitivity and specificity in assessing the risk of Down In 2019, the Korean Society of Maternal Fetal Medicine prepared medical guidelines for NIPT, with recommendations to inform and offer NIPT choice to all pregnant women, preferentially for women with high-risk pregnancies, to screen for trisomy 21, 18, and 13 and sex chromosome aneuploidy [6]. In Korea, highrisk pregnancies, including those in women with advanced maternal age (35 years or older), are steadily increasing [7], and it is expected that the use of NIPT will expand among these women.…”
Section: Introductionmentioning
confidence: 99%
“…Noninvasive prenatal testing (NIPT) is a method to screen for chromosomal abnormalities in the fetus, such as Down syndrome, Patau syndrome, and Edward syndrome, using cell-free DNA fragments from the fetus that are circulating in a pregnant woman's blood [1]. In particular, NIPT has been reported to have high sensitivity and specificity in assessing the risk of Down In 2019, the Korean Society of Maternal Fetal Medicine prepared medical guidelines for NIPT, with recommendations to inform and offer NIPT choice to all pregnant women, preferentially for women with high-risk pregnancies, to screen for trisomy 21, 18, and 13 and sex chromosome aneuploidy [6]. In Korea, highrisk pregnancies, including those in women with advanced maternal age (35 years or older), are steadily increasing [7], and it is expected that the use of NIPT will expand among these women.…”
Section: Introductionmentioning
confidence: 99%